Treatment with pharmacological inhibitors of EZH2 may represent a promising clinical application for the treatment of various cancers (22, 43); however, such an approach may not be appropriate for EBV-positive cancers, as EZH2-KO caused increased viral replication and progeny production (Fig. 5 and 6), which may exacerbate viral transmission and disease burden. The gene discussed is EZH2; the disease is cancer.